Uni-Bio Science Group Limited (HKG:0690)
Hong Kong · Delayed Price · Currency is HKD 0.1620
-0.0030 (-1.82%)
Sep 8, 2025, 4:08 PM HKT
Uni-Bio Science Group Revenue
Uni-Bio Science Group had revenue of 310.23M HKD in the half year ending June 30, 2025, with 24.12% growth. This brings the company's revenue in the last twelve months to 589.59M, up 15.97% year-over-year. In the year 2024, Uni-Bio Science Group had annual revenue of 552.98M with 14.08% growth.
Revenue (ttm)
589.59M
Revenue Growth
+15.97%
P/S Ratio
1.64
Revenue / Employee
1.17M
Employees
487
Market Cap
967.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 552.98M | 68.26M | 14.08% |
| Dec 31, 2023 | 484.72M | 44.40M | 10.08% |
| Dec 31, 2022 | 440.32M | 86.91M | 24.59% |
| Dec 31, 2021 | 353.41M | 144.63M | 69.27% |
| Dec 31, 2020 | 208.78M | -673.00K | -0.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| WuXi Biologics | 21.98B |
| Akeso | 2.75B |
| CSPC Pharmaceutical Group | 28.49B |
Uni-Bio Science Group News
- 10 months ago - Uni-Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches : Pioneering Entry into the High-Growth Medical Aesthetics Market - Zawya